Generic and biosimilar medicines manufacturer Sandoz has announced an investment of approximately US$90m (A$131.8m) at its site in Ljubljana, Slovenia to establish a dedicated Sandoz Biopharma Development Center by 2026. With this investment, the Ljubljana site will become one of the key locations for biosimilar product development at Sandoz. The new site may lead to the creation of approximately 200 new full-time jobs and aims to further strengthen the company’s capabilities in end-to-end drug substance and drug product development of biosimilars. The planned investment complements recently announced Sandoz plans to invest at least US$400m (A$586m) in a new biologics manufacturing plant in Lendava, Slovenia, as well as expanding its biosimilar development capabilities at its facility in Holzkirchen, Germany. It also builds on existing small molecule product development capabilities in Ljubljana, where Sandoz stated it had established comprehensive capabilities to develop technologically complex generic pharmaceuticals. Chief Scientific Officer Claire D’Abreu Hayling shared, “the new Biosimilar Development Center in Ljubljana, Slovenia, will build on these capabilities, helping Sandoz to meet rapidly rising global demand for biosimilars and to make an even more meaningful contribution to the long-term viability of healthcare systems around the world”.